Andromeda Biotech has dosed the first patient in its extension study of its Phase III DIA-AID 2 trial of DiaPep277 for the treatment of type 1 diabetes. The open-label, 24-month extension study is designed to evaluate long-term safety, tolerability, and the effect of DiaPep277 on the ability of patients to maintain glycemic control for two additional years following the completion of the confirmatory study, which is expected to conclude at the end of 2014. The extension study will be conducted i...